8-K: Progyny Reports Record FY25, Strong Q4; Issues Upbeat 2026 Guidance

Progyny, a leader in women's health and family building solutions, announced record full-year 2025 financial results and provided optimistic guidance for 2026.

Summary

• Fourth Quarter 2025 revenue reached $318.4 million, a 6.7% increase compared to Q4 2024, or 21% growth when excluding the impact of a large, former client.
• Full Year 2025 revenue was $1,288.7 million, a 10% increase over FY 2024, or 20% growth when excluding the impact of a large, former client.
• Gross profit for Q4 2025 increased by 21% to $76.9 million, yielding a gross margin of 24.1%, a 280 basis point increase year-over-year.
• Full Year 2025 gross profit increased by 20% to $304.5 million, with a gross margin of 23.6%, a 190 basis point increase year-over-year.
• Adjusted EBITDA for Q4 2025 grew 8.2% to $51.4 million, resulting in a 16.1% Adjusted EBITDA margin, a 20 basis point increase.
• Full Year 2025 Adjusted EBITDA increased by 12% to $222.1 million, with a 17.2% Adjusted EBITDA margin, a 20 basis point increase.
• Operating cash flow generated in FY 2025 was $210.2 million, up from $179.1 million in the prior year.
• The company repurchased 3,301,596 shares for $83.6 million during Q4 2025, bringing the total repurchased to approximately 6.5 million shares for $160 million under the November 2025 program, with over $40 million remaining.
• Progyny had 555 fertility and family building clients as of December 31, 2025, an increase from 473 clients as of December 31, 2024.
• Average eligible members increased by 4% to 6,707,000 in Q4 2025 compared to the prior year period.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance report, with record financial metrics, effective capital allocation through share repurchases, and optimistic forward guidance, despite the impact of a former large client. The company's growth in clients and operational efficiencies are positive indicators.

Positives

• Achieved record full year revenue, Adjusted EBITDA, and operating cash flow in 2025.
• Strong revenue growth of 21% in Q4 2025 and 20% in FY 2025, excluding the impact of a large former client, demonstrating underlying business strength.
• Significant gross profit margin expansion (280 basis points in Q4, 190 basis points in FY) due to ongoing efficiencies in care management services.
• Adjusted EBITDA margin expanded by 20 basis points in both Q4 and FY 2025, indicating improved profitability.
• Generated robust operating cash flow of $210.2 million in FY 2025, reflecting higher profitability and effective working capital management.
• Successfully maintained targeted 75%+ conversion of Adjusted EBITDA to operating cash flow.
• Active share repurchase program returned approximately $160 million to shareholders to date, with over $40 million remaining under authorization.
• Maintained a strong balance sheet with $310.1 million in cash, cash equivalents, and marketable securities, and no debt.
• Improved Days Sales Outstanding (DSO) by over 8 days to 62.3 days as of December 2025, indicating better revenue cycle management.
• Increased client base to 555 as of December 31, 2025, from 473 in the prior year, and a 4% increase in average eligible members.

Negatives

• Pharmacy benefit services revenue decreased by 1.1% in Q4 2025 to $109.8 million compared to $111.0 million in Q4 2024.
• Female utilization rate for the full year 2025 slightly decreased to 1.04% from 1.07% in the prior year.
• ART Cycles per Unique Female Utilizer for the full year 2025 slightly decreased to 0.93 from 0.94 in the prior year.
• Reported Q1 2026 revenue guidance reflects a potential growth of (1.6)% to 2.5%, which is a decline at the low end, although it is positive when excluding the former large client.

Risks

• Failure to meet publicly announced guidance or other expectations about the business.
• Competition in the market in which the company operates.
• History of operating losses and ability to sustain profitability.
• Unfavorable conditions in the industry or the United States economy.
• Limited operating history and difficulty in predicting future results of operations.
• Ability to attract and retain clients and increase the adoption of services within the client base.
• Loss of any of the largest client accounts.
• Changes in the technology industry or developments in the health insurance market.
• Negative publicity in the health benefits industry.
• Lags, failures, or security breaches in computer systems or those of vendors.
• A significant change in the utilization of solutions.
• Ability to offer high-quality support and obtain positive references from existing clients.
• Ability to develop and expand marketing and sales capabilities.
• The rate of growth of future revenue.
• Accuracy of the estimates and assumptions used to determine the size of target markets.
• Ability to successfully manage growth.
• Reductions in employee benefits spending.
• Seasonal fluctuations in sales.
• Adoption of new solutions and services by clients or members.
• Ability to innovate and develop new offerings.
• Ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences.
• Ability to maintain and enhance the brand.
• Ability to attract and retain members of the management team, key employees, or other qualified personnel.
• Risks related to any litigation against the company.
• Ability to maintain the Center of Excellence network of healthcare providers.
• Strategic relationships with and monitoring of third parties.
• Ability to maintain the pharmacy distribution network if there is a disruption to the network or its associated supply chains.
• Relationship with key pharmacy program partners or any decline in rebates provided by them.
• Ability to maintain relationships with benefits consultants.
• Exposure to credit risk from members.
• Risks related to government regulation and business with government entities.
• Ability to protect intellectual property rights.
• Risks related to acquisitions, strategic investments, or partnerships.
• Federal tax reform and changes to the effective tax rate; imposition of state and local state taxes.
• Ability to utilize a portion of net operating loss or research tax credit carryforwards.
• Ability to develop or maintain effective internal control over financial reporting.
• Ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices.

Future Outlook

The company projects full-year 2026 revenue between $1.355 billion and $1.405 billion, reflecting growth of 5.1% to 9.0% (or 9.3% to 13.3% excluding the former large client). Net income is expected to range from $95.4 million to $106.1 million, and Adjusted EBITDA from $224.0 million to $239.0 million. Progyny anticipates having approximately 600 clients, representing an estimated 7.2 million covered lives in 2026, with member activity continuing to remain healthy.

Management Comments

• "We're pleased to report that 2025 ended strongly, concluding a record year for Progyny, one in which we achieved our highest ever levels of full year revenue, Adjusted EBITDA, and operating cash flow." Pete Anevski, Chief Executive Officer.
• "These results reflect how our model provides us with the ability to both expand the business while simultaneously investing for future growth." Pete Anevski, Chief Executive Officer.
• "As 2026 begins, we're excited for the significant opportunities ahead as we continue to expand our presence with large self-insured employers, both in the US and globally, while also launching our newest program for the fully insured market." Pete Anevski, Chief Executive Officer.
• "The fourth quarter and full year results reflect strong revenue growth and margin expansion." Mark Livingston, Chief Financial Officer.
• "Under our latest share repurchase program, we acquired more than 3.3 million shares during the fourth quarter, and approximately 6.5 million shares to date, returning approximately $160 million in capital to our shareholders." Mark Livingston, Chief Financial Officer.
• "Even so, the 2026 guidance ranges we are issuing today reflect the potential for variability in member engagement, which is consistent with the approach we've been following for well over a year." Pete Anevski, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Progyny operates in the growing women's health and family building solutions market, a sector increasingly prioritized by large self-insured employers and expanding into the fully insured market. The company's focus on comprehensive, inclusive solutions and a premier network of specialists positions it to capitalize on the demand for high-quality, cost-effective fertility and family benefits, aligning with broader trends of employers enhancing employee benefits to attract and retain talent.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, active share repurchase program, and optimistic future guidance, suggesting potential for increased shareholder value.
• Employees: Continued investment in platform expansion and integration of acquisitions indicates ongoing company growth, potentially leading to stable or expanding employment opportunities.
• Customers (Clients): Growth in clients and covered lives demonstrates successful client acquisition and retention, reinforcing the value proposition of Progyny's services.
• Members: Healthy member activity and the upcoming launch of a new program for the fully insured market suggest continued and expanded access to fertility and family building benefits.

Next Steps

• Launch of the newest program for the fully insured market.
• Continue to expand presence with large self-insured employers, both in the US and globally.
• Complete early launches from accounts won in the most recent selling season over the coming months.

Key Dates

Recommendation

The company delivered record full-year financial results, demonstrating robust revenue growth and margin expansion even after excluding a large former client. The proactive share repurchase program signals confidence in valuation and returns capital to shareholders. With a strong balance sheet, increasing client base, and positive 2026 guidance, the company is well-positioned for continued growth in a high-demand market, making it an attractive investment.

Keywords

fertility benefits, family building, women's health, employee benefits, healthcare solutions, ART cycles, IVF, employer benefits, pharmacy benefits, corporate wellness, earnings report, financial results